Huons Meditech Selected for Government Raw Materials Manufacturing Support Project

Biohealth Industry Supply Chain Stability Support Project by the Korea Health Industry Development Institute

Huons Meditech Co., Ltd. (Huons Meditech, 200670) announced on May 13 that it was recently selected for the '2026 Biohealth Industry Supply Chain Stability Support Project'—specifically, for the 'Domestic Raw and Subsidiary Materials Manufacturing Support Project'—hosted by the Korea Health Industry Development Institute.

With this selection, Huons Meditech plans to invest a total amount in the tens of billions of won, including support funding over the first and second years, to advance the manufacturing process for high-purity sterile sodium hyaluronate and accelerate its entry into the global market.

Through this project, Huons Meditech aims to lay the foundation for entering the public procurement market while also securing global quality competitiveness targeting the overseas pharmaceutical and bio markets.

In particular, in line with efforts by other domestic pharmaceutical companies using sterile sodium hyaluronate as a raw material to enter the Japanese market, Huons Meditech plans to pursue registration with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Subsequently, after additional verification and certification in accordance with global standards, the company intends to expand its product supply to overseas bio companies in earnest.

Furthermore, Huons Meditech plans to maximize its production capacity by expanding facilities through the 'Domestic Raw and Subsidiary Materials Manufacturing Support Project.' By securing the capability to supply products that meet international quality standards in a timely manner, the company aims to increase both domestic and international supply and exports of domestic raw and subsidiary materials over the mid- to long-term.

Meanwhile, Huons Meditech is also working to increase its market share in freeze-dried products by introducing new freeze-drying production facilities and leak and foreign matter inspection machines capable of inspecting freeze-dried products. Through the production and sale of new freeze-dried products, the company plans to improve plant utilization rates and productivity.

Kang Minjong, CEO of Huons Meditech, stated, "Through this project and the expansion of our freeze-drying line, we will establish manufacturing and quality management know-how and expand into the development of bio raw materials and healthcare materials in the future," adding, "We aim to become a world-class biohealth production base and contribute to the advancement of the national bio industry."

This content was produced with the assistance of AI translation services.